From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: ACITRETIN
BIMEKIZUMAB · Limited Use, codes 641
Indications
Bimzelx (bimekizumab injection) is indicated for:
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
• Psoriasis (PsO)
The treatment of moderate to severe plaque psoriasis in adult patients who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
• Psoriatic arthritis (PsA)
The treatment of adult patients with active psoriatic arthritis. Bimzelx can be used alone or in
combination with a conventional non-biologic disease-modifying antirheumatic drug (cDMARD)
(e.g., methotrexate).
PM: https://pdf.hres.ca/dpd_pm/00082779.PDF; date 2025-12-12; DIN 02525267; fetched 2026-09-10
Product monograph
ACITRETIN · General benefit
1 INDICATIONS
SORIATANE (acitretin) is indicated for:
• Severe psoriasis (includes erythrodermic and pustular types)
• Other disorders of keratinization
Severe psoriasis is a condition that involves more than 10% of body surface area or is physically,
occupationally or psychologically disabling.
PM: https://pdf.hres.ca/dpd_pm/00080165.PDF; date APR 04, 2025; DIN 02070847; fetched 2026-09-10
Product monograph
ADALIMUMAB · Limited Use, codes 600, 601, 602, 603, 604, 605, 606, 607, 609, 611 (23), Limited Use, codes 600, 602, 603, 604, 605, 606, 607, 609, 633, 634 (7)
Indications
AMGEVITA is indicated for:
Rheumatoid Arthritis
• reducing the signs and symptoms, inducing major clinical response and clinical remission,
inhibiting the progression of structural damage and improving physical function in adult
patients with moderately to severely active rheumatoid arthritis (RA).
PM: https://pdf.hres.ca/dpd_pm/00085868.PDF; date not captured; DIN 02459299; fetched 2026-09-10
Product monograph
APREMILAST · Off-Formulary Interchangeable, not an ODB benefit
Indications
• Plaque Psoriasis
OTEZLA (apremilast) is indicated for the treatment of adult patients with moderate to
severe plaque psoriasis who are candidates for phototherapy or systemic therapy.
PM: https://pdf.hres.ca/dpd_pm/00084256.PDF; date 2026-04-10; DIN 02434318; fetched 2026-09-10
Product monograph
BARICITINIB · Limited Use, codes 615, 734 (1), Limited Use, codes 734 (1)
1 INDICATIONS
OLUMIANT (baricitinib tablets) is indicated for:
Rheumatoid Arthritis (RA)
• In combination with methotrexate (MTX), for reducing the signs and symptoms of moderate
to severe rheumatoid arthritis (RA) in adult patients who have responded inadequately to
one or more disease-modifying anti-rheumatic drugs (DMARDs).
PM: https://pdf.hres.ca/dpd_pm/00074394.PDF; date not captured; DIN 02480018; fetched 2026-09-10
Product monograph
CYCLOSPORINE · Off-Formulary Interchangeable, not an ODB benefit (2), General benefit (8)
Psoriasis
NEORAL capsules and oral solution (cyclosporine) are indicated for the treatment of severe psoriasis in
patients for whom conventional therapy is ineffective or inappropriate.
PM: https://pdf.hres.ca/dpd_pm/00085584.PDF; date 2026-07-30; DIN 02150662; fetched 2026-09-10
Product monograph
ETANERCEPT · Limited Use, codes 512, 513, 514, 563, 591 (3), Limited Use, codes 498, 499, 514, 563, 591 (4)
• treatment of adult patients with chronic moderate to severe plaque psoriasis (PsO) who are
candidates for systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00083562.PDF; date August 31, 2016; DIN 02455323; fetched 2026-09-10
Product monograph
HYDROCORTISONE · General benefit (6), Temporary benefit (1), Listed, not a benefit (2)
• Neoplastic Diseases: For palliative management of: leukemias and lymphomas in adults, acute
leukemia of childhood.
PM: https://pdf.hres.ca/dpd_pm/00082414.PDF; date OCT 20, 2025; DIN 00030910; fetched 2026-09-10
Product monograph
INFLIXIMAB · Limited Use, codes 468, 469, 470, 471, 477, 478, 479 (2), Limited Use, codes 541, 542, 543, 544, 545, 546, 547 (1), Limited Use, codes 715, 716, 718 (2), Limited Use, codes 592, 593, 594, 595, 596, 597, 598 (1)
• treatment of adult patients with chronic moderate to severe plaque psoriasis who are candidates
for systemic therapy. For patients with chronic moderate plaque psoriasis, RemdantryTM should
be used after phototherapy has been shown to be ineffective or inappropriate. When assessing
the severity of psoriasis, the health professional should consider the extent of involvement,
location of lesions, response to previous treatments, and impact of disease on the patient’s
PM: https://pdf.hres.ca/dpd_pm/00081840.PDF; date September 2, 2025; DIN 02419475; fetched 2026-09-10
Product monograph
RISANKIZUMAB · Limited Use, codes 574
Indications
SKYRIZI (risankizumab injection) is indicated for:
• the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for
systemic therapy or phototherapy.
PM: https://pdf.hres.ca/dpd_pm/00085642.PDF; date 2026-07-08; DIN 02519283; fetched 2026-09-10
Product monograph
and 2 more
Coverage source: ON formulary extract 2026-08-26